当前位置: 首页 >> 检索结果
241. Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss.
作者: Kate Hallsworth.;Gulnar Fattakhova.;Kieren G Hollingsworth.;Christian Thoma.;Sarah Moore.;Roy Taylor.;Christopher P Day.;Michael I Trenell.
来源: Gut. 2011年60卷9期1278-83页
Lifestyle interventions focusing on weight loss remain the cornerstone of non-alcoholic fatty liver disease (NAFLD) management. Despite this, the weight losses achieved in research trials are not easily replicated in the clinic and there is an urgent need for therapies independent of weight loss. Aerobic exercise is not well sustained and the effectiveness of the better tolerated resistance exercise upon liver lipid and mediators of liver lipid has not been assessed.
242. Randomised placebo-controlled trial of rituximab (anti-CD20) in active ulcerative colitis.
作者: Keith Leiper.;Kate Martin.;Anthony Ellis.;Sreedhar Subramanian.;Alastair J Watson.;Steve E Christmas.;Deborah Howarth.;Fiona Campbell.;Jonathan M Rhodes.
来源: Gut. 2011年60卷11期1520-6页
To assess the safety and efficacy of the B lymphocyte (anti-CD20) antibody, rituximab, in the treatment of steroid-resistant moderately active ulcerative colitis (UC).
243. A novel reflux inhibitor lesogaberan (AZD3355) as add-on treatment in patients with GORD with persistent reflux symptoms despite proton pump inhibitor therapy: a randomised placebo-controlled trial.
作者: Guy E Boeckxstaens.;Hanneke Beaumont.;Jan G Hatlebakk.;Debra G Silberg.;Karin Björck.;Maria Karlsson.;Hans Denison.
来源: Gut. 2011年60卷9期1182-8页
o evaluate the efficacy and tolerability of add-on treatment with lesogaberan (AZD3355), a novel reflux inhibitor, in patients with persistent gastro-oesophageal reflux disease (GORD) symptoms despite proton pump inhibitor (PPI) therapy.
244. The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study.
作者: Séverine Vermeire.;Subrata Ghosh.;Julian Panes.;Jens F Dahlerup.;Andreas Luegering.;Jana Sirotiakova.;Ulrike Strauch.;Gary Burgess.;Jacqueline Spanton.;Steven W Martin.;Wojciech Niezychowski.
来源: Gut. 2011年60卷8期1068-75页
Leucocyte migration to gut mucosa, mediated by integrin binding to mucosal addressin cell adhesion molecule (MAdCAM), is a promising target for therapeutic intervention in inflammatory bowel disease. This first-in-human study of a monoclonal antibody to MAdCAM, PF-00547,659, aimed to explore the safety and preliminary efficacy of this gut-specific mechanism in ulcerative colitis.
245. A randomised trial of sheathed versus standard forceps for obtaining uncontaminated biopsy specimens of microbiota from the terminal ileum.
作者: Maneesh Dave.;Laura A Johnson.;Seth T Walk.;Vincent B Young.;Ryan W Stidham.;Meghana N Chaudhary.;Jessica Funnell.;Peter D R Higgins.
来源: Gut. 2011年60卷8期1043-9页
The study of intestinal microbiota has been revolutionised by the use of molecular methods, including terminal restriction fragment length polymorphism (T-RFLP) analysis. Microbiota studies of Crohn's disease patients have examined samples from stool or from the neoterminal ileum with a standard biopsy forceps, which could be contaminated by colonic bacteria when the forceps passes through the colonoscope channel.
246. Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome.
作者: P B Jeppesen.;R Gilroy.;M Pertkiewicz.;J P Allard.;B Messing.;S J O'Keefe.
来源: Gut. 2011年60卷7期902-14页
Teduglutide, a GLP-2 analogue, may restore intestinal structural and functional integrity by promoting repair and growth of the mucosa and reducing gastric emptying and secretion, thereby increasing fluid and nutrient absorption in patients with short bowel syndrome (SBS). This 24-week placebo-controlled study evaluated the ability of teduglutide to reduce parenteral support in patients with SBS with intestinal failure.
247. Colorectal cancer screening with odour material by canine scent detection.
作者: Hideto Sonoda.;Shunji Kohnoe.;Tetsuro Yamazato.;Yuji Satoh.;Gouki Morizono.;Kentaro Shikata.;Makoto Morita.;Akihiro Watanabe.;Masaru Morita.;Yoshihiro Kakeji.;Fumio Inoue.;Yoshihiko Maehara.
来源: Gut. 2011年60卷6期814-9页
Early detection and early treatment are of vital importance to the successful treatment of various cancers. The development of a novel screening method that is as economical and non-invasive as the faecal occult blood test (FOBT) for early detection of colorectal cancer (CRC) is needed. A study was undertaken using canine scent detection to determine whether odour material can become an effective tool in CRC screening.
248. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study.
作者: George V Papatheodoridis.;Spilios Manolakopoulos.;Giota Touloumi.;Georgia Vourli.;Maria Raptopoulou-Gigi.;Irini Vafiadis-Zoumbouli.;Themistoklis Vasiliadis.;Kostas Mimidis.;Charalambos Gogos.;Ioannis Ketikoglou.;Emanuel K Manesis.; .
来源: Gut. 2011年60卷8期1109-16页
To evaluate the risk and predictors of hepatocellular carcinoma (HCC) in HBeAg-negative chronic hepatitis B patients of the large HEPNET.Greece cohort study who received long-term oral antivirals starting with lamivudine monotherapy.
249. Randomised, double-blind, placebo-controlled trial of fructo-oligosaccharides in active Crohn's disease.
作者: Jane L Benjamin.;Charlotte R H Hedin.;Andreas Koutsoumpas.;Siew C Ng.;Neil E McCarthy.;Ailsa L Hart.;Michael A Kamm.;Jeremy D Sanderson.;Stella C Knight.;Alastair Forbes.;Andrew J Stagg.;Kevin Whelan.;James O Lindsay.
来源: Gut. 2011年60卷7期923-9页
The commensal intestinal microbiota drive the inflammation associated with Crohn's disease. However, bacteria such as bifidobacteria and Faecalibacterium prausnitzii appear to be immunoregulatory. In healthy subjects the intestinal microbiota are influenced by prebiotic carbohydrates such as fructo-oligosaccharides (FOS). Preliminary data suggest that FOS increase faecal bifidobacteria, induce immunoregulatory dendritic cell (DC) responses and reduce disease activity in patients with Crohn's disease.
250. Stepwise radical endoscopic resection versus radiofrequency ablation for Barrett's oesophagus with high-grade dysplasia or early cancer: a multicentre randomised trial.
作者: Frederike G I van Vilsteren.;Roos E Pouw.;Stefan Seewald.;Lorenza Alvarez Herrero.;Carine M T Sondermeijer.;Mike Visser.;Fiebo J W Ten Kate.;Karl C Yu Kim Teng.;Nib Soehendra.;Thomas Rösch.;Bas L A M Weusten.;Jacques J G H M Bergman.
来源: Gut. 2011年60卷6期765-73页
After focal endoscopic resection (ER) of high-grade dysplasia (HGD) or early cancer (EC) in Barrett's oesophagus (BO), eradication of all remaining BO reduces the recurrence risk. The aim of this study was to compare the safety of stepwise radical ER (SRER) versus focal ER followed by radiofrequency ablation (RFA) for complete eradication of BO containing HGD/EC.
251. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial.
作者: Walter Reinisch.;William J Sandborn.;Daniel W Hommes.;Geert D'Haens.;Stephen Hanauer.;Stefan Schreiber.;Remo Panaccione.;Richard N Fedorak.;Mary Beth Tighe.;Bidan Huang.;Wendy Kampman.;Andreas Lazar.;Roopal Thakkar.
来源: Gut. 2011年60卷6期780-7页
The aim of this study was to assess the efficacy and safety of adalimumab (ADA), a recombinant human monoclonal antibody against tumour necrosis factor α (TNF), for the induction of clinical remission in anti-TNF naïve patients with moderately to severely active ulcerative colitis.
252. BMI is superior to symptoms in predicting response to proton pump inhibitor: randomised trial in patients with upper gastrointestinal symptoms and normal endoscopy.
作者: Jonathan Fletcher.;Mohammad H Derakhshan.;Gareth-Rhys Jones.;Angela A Wirz.;Kenneth E L McColl.
来源: Gut. 2011年60卷4期442-8页
In most patients undergoing endoscopy for upper gastrointestinal (GI) symptoms in the Western world, no macroscopic abnormality or evidence of Helicobacter pylori infection is identified. Following this negative investigation, proton pump inhibitor (PPI) therapy is usually prescribed. The aim of this study was to assess the value of such treatment compared with placebo and to identify predictors of response.
253. Pancolonic chromoendoscopy with indigo carmine versus standard colonoscopy for detection of neoplastic lesions: a randomised two-centre trial.
作者: Jürgen Pohl.;Arved Schneider.;Hartmut Vogell.;Gerhard Mayer.;Gernot Kaiser.;Christian Ell.
来源: Gut. 2011年60卷4期485-90页
Colonoscopy is the accepted gold standard for detecting colorectal adenomas, but the miss rate, especially for small and flat lesions, remains unacceptably high. The aim of this study was to determine whether enhanced mucosal contrast using pancolonic chromoendoscopy (PCC) allows higher rates of adenoma detection.
254. Endoscopic retrograde pancreatography criteria to diagnose autoimmune pancreatitis: an international multicentre study.
作者: Aravind Sugumar.;Michael J Levy.;Terumi Kamisawa.;G J Webster.;Myung-Hwan Kim.;Felicity Enders.;Zahir Amin.;Todd H Baron.;Mike H Chapman.;Nicholas I Church.;Jonathan E Clain.;Naoto Egawa.;Gavin J Johnson.;Kazuichi Okazaki.;Randall K Pearson.;Stephen P Pereira.;Bret T Petersen.;Samantha Read.;Raghuwansh P Sah.;Neomal S Sandanayake.;Naoki Takahashi.;Mark D Topazian.;Kazushige Uchida.;Santhi Swaroop Vege.;Suresh T Chari.
来源: Gut. 2011年60卷5期666-70页
Characteristic pancreatic duct changes on endoscopic retrograde pancreatography (ERP) have been described in autoimmune pancreatitis (AIP). The performance characteristics of ERP to diagnose AIP were determined.
255. E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided 'Constant-care' approach.
作者: Margarita Elkjaer.;Mary Shuhaibar.;Johan Burisch.;Yvonne Bailey.;Hanne Scherfig.;Birgit Laugesen.;Søren Avnstrøm.;Ebbe Langholz.;Colm O'Morain.;Elsebeth Lynge.;Pia Munkholm.
来源: Gut. 2010年59卷12期1652-61页
The natural history of ulcerative colitis requires continuous monitoring of medical treatment via frequent outpatient visits. The European health authorities' focus on e-health is increasing. Lack of easy access to inflammatory bowel disease (IBD) clinics, patients' education and understanding of the importance of early treatment at relapse is leading to poor compliance. To overcome these limitations a randomised control trial 'Constant-care' was undertaken in Denmark and Ireland.
256. Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301).
作者: Laetitia Dahan.;Frank Bonnetain.;Marc Ychou.;Emmanuel Mitry.;Mohamed Gasmi.;Jean-Luc Raoul.;Stéphane Cattan.;Jean-Marc Phelip.;Pascal Hammel.;Bruno Chauffert.;Pierre Michel.;Jean-Louis Legoux.;Philippe Rougier.;Laurent Bedenne.;Jean-François Seitz.; .
来源: Gut. 2010年59卷11期1527-34页
Gemcitabine is the standard chemotherapy for patients with metastatic pancreatic adenocarcinoma. Although the 5-fluorouracil (5FU), folinic acid and cisplatin combination (LV5FU2-CDDP) is an option, the optimal order of the regimens must be determined. The first strategic phase III trial comparing LV5FU2-CDDP followed by gemcitabine versus gemcitabine followed by LV5FU2-CDDP was conducted.
257. Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis.
作者: William J Sandborn.;Jean Frederic Colombel.;Matthew Frankel.;Daan Hommes.;James N Lowder.;Lloyd Mayer.;Scott Plevy.;Pieter Stokkers.;Simon Travis.;Gert Van Assche.;Daniel C Baumgart.;Stephan R Targan.
来源: Gut. 2010年59卷11期1485-92页
Pilot studies with visilizumab, a humanised monoclonal antibody to CD3, suggest efficacy for corticosteroid-refractory ulcerative colitis (UC). A placebo-controlled trial was warranted.
258. Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial.
作者: Marco Romano.;Antonio Cuomo.;Antonietta G Gravina.;Agnese Miranda.;Maria Rosaria Iovene.;Angelo Tiso.;Mariano Sica.;Alba Rocco.;Raffaele Salerno.;Riccardo Marmo.;Alessandro Federico.;Gerardo Nardone.
来源: Gut. 2010年59卷11期1465-70页
Antimicrobial drug resistance is a major cause of the failure of Helicobacter pylori eradication and is largely responsible for the decline in eradication rate. Quadruple therapy has been suggested as a first-line regimen in areas with clarithromycin resistance rate >15%. This randomised trial aimed at evaluating the efficacy of a levofloxacin-containing sequential regimen in the eradication of H pylori-infected patients in a geographical area with >15% prevalence of clarithromycin resistance versus a clarithromycin containing sequential therapy.
259. Danoprevir, an HCV NS3/4A protease inhibitor, improves insulin sensitivity in patients with genotype 1 chronic hepatitis C.
作者: Rami Moucari.;Nicole Forestier.;Dominique Larrey.;Dominique Guyader.;Patrice Couzigou.;Yves Benhamou.;Hélène Voitot.;Michel Vidaud.;Scott Seiwert.;Bill Bradford.;Stefan Zeuzem.;Patrick Marcellin.
来源: Gut. 2010年59卷12期1694-8页
Insulin resistance (IR) is a major predictor of treatment failure in patients with hepatitis C virus (HCV) infection treated with peginterferon/ribavirin. The aim of this study was to evaluate the short-term effect of an HCV protease inhibitor monotherapy on IR in parallel with an antiviral effect.
260. High detection rate of adenomas in familial colorectal cancer.
作者: A E van der Meulen-de Jong.;H Morreau.;M C J M Becx.;L F S J Crobach.;M van Haastert.;W R ten Hove.;J H Kleibeuker.;M A C Meijssen.;F M Nagengast.;M C M Rijk.;J M J I Salemans.;A Stronkhorst.;H A R E Tuynman.;J Vecht.;M L Verhulst.;W H de Vos tot Nederveen Cappel.;H Walinga.;O K Weinhardt.;B D Westerveld.;A M C Witte.;H J Wolters.;H F A Vasen.
来源: Gut. 2011年60卷1期73-6页
Subjects with one first-degree relative (FDR) with colorectal cancer (CRC) <50 years old or two FDRs with CRC have an increased risk for CRC (RR 4-6). Current guidelines recommend colonoscopic surveillance of such families. However, information about the yield of surveillance is limited. The aim of the present study was to evaluate the outcome of surveillance and to identify risk factors for the development of adenomas.
|